

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Securities Code: 7775

June 3, 2024

Start date of measures for electronic provision: May 29, 2024

To Our Shareholders:

Keiichi Yamada
Representative Director and President
DAIKEN MEDICAL CO., LTD.
2-6-2 Ayumino, Izumi-shi, Osaka, Japan

NOTICE OF THE 56TH ANNUAL GENERAL MEETING OF SHAREHOLDERS

We are pleased to notify you that the 56th Annual General Meeting of Shareholders of DAIKEN MEDICAL CO., LTD. (the “Company”) will be held as follows.

When convening this general meeting of shareholders, the Company takes measures for providing information that constitutes the content of reference documents for the general meeting of shareholders, etc. (items for which measures for providing information in electronic format are to be taken) in electronic format, and posts this information on each of the following websites. Please access any of these websites to review the information.

The Company’s website:

<https://www.daiken-iki.co.jp/ir/soukai.php> (in Japanese)

Website for posted informational materials for the general meeting of shareholders:

<https://d.sokai.jp/7775/teiji/> (in Japanese)

Tokyo Stock Exchange website (Listed Company Search):

<https://www2.jpx.co.jp/tseHpFront/JJK010010Action.do?Show=Show> (in Japanese)

(Access the TSE website by using the link shown above, enter “Daiken Medical” in “Issue name (company name)” or the Company’s securities code “7775” in “Code,” and click “Search.” Then, click “Basic information” and select “Documents for public inspection/PR information.” Under “Filed information available for public inspection,” click “Click here for access” under “Notice of General Shareholders Meeting /Informational Materials for a General Shareholders Meeting.”)

If you are not attending the meeting, you may exercise your voting rights by any of the methods listed below. Please review the Reference Documents for the General Meeting of Shareholders and exercise your voting rights.

[Exercise of voting rights via the Internet]

Please access the Company’s designated website for the exercise of voting rights (<https://evote.tr.mufg.jp/>), and follow the guide on the screen to enter your vote of approval or disapproval for each proposal by 5:30 p.m. on Wednesday, June 19, 2024 (JST).

[Exercise of voting rights in writing]

Please indicate your vote of approval or disapproval for each proposal on the voting form, and return it by mail so that it reaches us by 5:30 p.m. on Wednesday, June 19, 2024 (JST).

- 1. Date and Time:** Thursday, June 20, 2024 at 10:00 a.m. (JST)
- 2. Venue:** Sanraku Ballroom, RIHGA Royal Hotel Osaka
5-3-68 Nakanoshima, Kita-ku, Osaka-shi, Osaka, Japan
(The venue is different from the previous meeting. Please double-check the above address to ensure arrival at the correct venue on the day of the meeting.)

3. Objective

Items to be reported: 56th term (from April 1, 2023 to March 31, 2024)
Reporting the Contents of Business Report and Financial Statements

Items to be resolved:

- Proposal No. 1** Election of Four Directors
- Proposal No. 2** Election of Three Audit & Supervisory Board Members

- When attending the meeting, please submit the voting form at the reception desk.
- When exercising your voting rights in writing (by mail), any proposal on the voting form with the vote for or against left unmarked will be regarded as a vote for the proposal.
- If you exercise your voting rights redundantly via the Internet, etc. and in writing, the voting rights exercised via the Internet, etc. shall be treated as valid.
- If you exercise your voting rights more than once via the Internet, etc., the Company will regard the content of the last exercise as valid.
- If revisions to the items subject to measures for electronic provision arise, a notice of the revisions and the details of the items before and after the revisions will be posted on each of the websites.
- The Company will send documentation containing the items subject to measures for electronic provision to all shareholders, regardless of whether they requested paper-based documents for the General Meeting of Shareholders. Among items subject to measures for electronic provision, the following items will not be provided in the paper-based documents sent, in accordance with laws and regulations and Article 14 of the Articles of Incorporation of the Company.
 - (1) “Company System and Policy” in the Business Report
 - (2) “Statement of Changes in Shareholders’ Equity” and “Notes to Financial Statements” in the Financial StatementsThe Business Report and Financial Statements contained in the paper-based documents are part of the documents audited by the Accounting Auditor when preparing accounting audit reports and the Audit & Supervisory Board when preparing audit reports.
- Please note that the results of the resolution will be posted on our website instead of sending a written notice of resolution.

Reference Documents for the General Meeting of Shareholders

Proposals and Reference Information

Proposal No. 1 Election of Four Directors

The terms of office of all four Directors will expire at the conclusion of this meeting. Director Mitsuru Yamada has resigned from his position as of December 31, 2023. Therefore, the Company proposes the election of four Directors including two Outside Directors.

The candidates for Directors are as follows:

Candidate No.	Name		Position and responsibility in the Company and significant concurrent positions outside the Company, etc.
1	Keiichi Yamada	Reelection	Representative Director and President, and General Manager of the New Business Division
2	Masayuki Yamada	Reelection	Director and Vice President (supervising Corporate Management)
3	Hiroshi Daikuya	Reelection Outside Independent	Outside Director President of Atstream Corporation Outside Auditor of ASANUMA CORPORATION Managing Partner of Atstream Partners LLC
4	Yoshimi Inagaki	Reelection Outside Independent	Outside Director Specially Appointed Professor, Nippon Medical School (Department of Anesthesiology)

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company		Number of the Company's shares owned					
1	Keiichi Yamada (February 15, 1958) Reelection	July 1982	Joined the Company as Director	5,462,120					
		Apr. 1989	Managing Director						
		Apr. 1997	Senior Managing Director						
		Mar. 2004	Representative Director and President						
		Oct. 2016	Director (in charge of Research)						
Apr. 2017	Director, Executive Officer, and General Manager of the Development Department I	Jan. 2019	Representative Director and President (in charge of the Technology Division)	Apr. 2021	Representative Director and President, and General Manager of the Technology Division and General Manager of the Administration Division	Apr. 2023	Representative Director and President, and General Manager of the New Business Division (current position)		
Number of years in office as a Director (at the conclusion of this meeting)		42 years							
Attendance at Board of Directors meetings for the fiscal year 2023		13/13 meetings							
Reasons for nomination as candidate for Director Keiichi Yamada has extensive business knowledge and experience in research and development and overall management. He has been involved in all aspects of corporate management as a Representative Director since 2004, and has demonstrated leadership in the Company's research and development after assuming that post. As he has been appropriately performing his duties in all aspects of management as the Representative Director and President again since January 2019, the Company believes that he is qualified to serve as a Director of the Company.									
Special interests There is no special interest between the candidate and the Company.									
2	Masayuki Yamada (January 6, 1960) Reelection	July 1982	Joined the Company as Director	3,129,720					
		Apr. 1989	Managing Director						
		June 2010	Senior Managing Director						
		Oct. 2016	Director (in charge of Development)						
		Apr. 2017	Director, Executive Officer, and General Manager of the Development Department II		Jan. 2019	Director and Vice President (in charge of the Administration Division)	Apr. 2019	Director and Vice President, and General Manager of the Sales Division and General Manager of the Administration Division	Apr. 2021
Number of years in office as a Director (at the conclusion of this meeting)		42 years							
Attendance at Board of Directors meetings for the fiscal year 2023		12/13 meetings							
Reasons for nomination as candidate for Director Masayuki Yamada has served as General Manager of the Sales Division and General Manager of the Product Planning Department since joining the Company, and has a wide range of abundant business knowledge and experience. He is currently performing his duties appropriately as Director and Vice President (supervising Corporate Management). Therefore, the Company believes that he is qualified to serve as a Director of the Company.									
Special interests There is no special interest between the candidate and the Company.									

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
3	Hiroshi Daikuya (July 15, 1968) Reelection Outside Independent	<p>Apr. 1991 Joined Arthur Andersen Certified Public Accountant Joint Office (currently KPMG AZSA LLC)</p> <p>Mar. 1994 Registered as a certified public accountant</p> <p>Apr. 1996 Transferred to Asahi Arthur Andersen Limited (currently PwC Consulting LLC)</p> <p>July 2001 Participated in the establishment of Atstream Consulting Corporation (currently Atstream Corporation) as Director</p> <p>June 2006 Outside Audit & Supervisory Board Member of the Company</p> <p>Oct. 2010 Outside Corporate Auditor of MIRAIT Holdings Corporation</p> <p>July 2013 President of Atstream Corporation (current position)</p> <p>June 2016 Outside Director of the Company (current position)</p> <p>June 2022 Outside Auditor of ASANUMA CORPORATION (current position)</p> <p>July 2022 Managing Partner of Atstream Partners LLC (current position)</p>	5,000
Number of years in office as a Director (at the conclusion of this meeting)		8 years	
Attendance at Board of Directors meetings for the fiscal year 2023		13/13 meetings	
<p>Reasons for nomination as candidate for Director</p> <p>Hiroshi Daikuya has served as an Outside Audit & Supervisory Board Member of the Company for 10 years from 2006, in addition to his professional knowledge as a certified public accountant, and is familiar with the Company's management situation. Therefore, the Company expects him to supervise the execution of duties by Directors and provide advice, etc. on overall management. There is no business relationship between the Company and the entity for which Mr. Daikuya concurrently serves as an officer.</p>			
<p>Special interests</p> <p>There is no special interest between the candidate and the Company.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned
4	Yoshimi Inagaki (October 27, 1956) Reelection Outside Independent	Feb. 2001 Assistant Professor, Faculty of Medicine, Tottori University (Department of Anesthesia and Resuscitation)	0
		Dec. 2005 Professor, Faculty of Medicine, Tottori University (Department of Anesthesiology and Critical Care Medicine)	
		Apr. 2008 General Manager, Operating Rooms, Tottori University Hospital	
		Apr. 2009 Vice Director, Tottori University Hospital	
		Apr. 2016 Director of Medical Engineering Center and Manager of Medical Equipment Safety Management, Tottori University Hospital	
		Apr. 2021 Professor, School of Medicine, International University of Health and Welfare (Department of Anesthesiology and Intensive Care Medicine)	
		June 2021 Outside Director of the Company (current position)	
		Apr. 2022 Manager of Medical Equipment Safety Management, IUHW Narita Hospital	
		Apr. 2023 General Manager of Department of Anesthesiology and Intensive Care, IUHW Narita Hospital	
		May 2024 Specially Appointed Professor, Nippon Medical School (Department of Anesthesiology) (current position)	
		Number of years in office as a Director (at the conclusion of this meeting)	3 years
		Attendance at Board of Directors meetings for the fiscal year 2023	13/13 meetings
		Reasons for nomination as candidate for Director Yoshimi Inagaki has professional knowledge as a physician and detailed insight into the status of use of the Company's products in hospitals. Therefore, the Company expects him to supervise the execution of duties by Directors and provide advice, etc. on product strategies based on trends in the medical field. There is no significant transaction between the Company and the university where he currently serves as a professor.	
		Special interests There is no special interest between the candidate and the Company.	

- Notes:
1. Hiroshi Daikuya is a candidate for Outside Director. Furthermore, he has been designated as an independent officer as provided for by Tokyo Stock Exchange, Inc. and has been notified to the Exchange. If he is elected as proposed, he will continue to be an independent officer.
 2. Yoshimi Inagaki is a candidate for Outside Director. Furthermore, he has been designated as an independent officer as provided for by Tokyo Stock Exchange, Inc. and has been notified to the Exchange. If he is elected as proposed, he will continue to be an independent officer.
 3. The Company has entered into a liability insurance contract for officers, etc. with an insurance company as provided for in Article 430-3, paragraph (1) of the Companies Act, and the insurance contract covers damages such as the costs of disputes and compensation for damages incurred by the insured due to company lawsuits, third-party lawsuits, shareholder derivative lawsuits, etc. The candidates will be included in the insured under the insurance contract. Furthermore, the Company plans to renew the insurance contract with the same terms at the next renewal.

(Reference) Skill matrix of candidates for Director

Knowledge and experience, etc. possessed by the candidates for Director discussed in Proposal No. 1 are as follows:

Knowledge, experience, capability, expertise, and strategic skills	Keiichi Yamada Representative Director and President	Masayuki Yamada Director and Vice President	Hiroshi Daikuya Outside Director	Yoshimi Inagaki Outside Director
Corporate management	●	●	●	
Technology and research & development	●			●
Corporate finance			●	
Legal affairs and risk management	●	●	●	
Global	●	●		●
Industrial knowledge	●	●		●
Clinical experience	●			●
Sustainability	●	●	●	
Challenge	●	●	●	
For Patients	●	●		●

Proposal No. 2 Election of Three Audit & Supervisory Board Members

The terms of office of all three Audit & Supervisory Board Members will expire at the conclusion of this general meeting of shareholders. Therefore, the Company proposes the election of three Audit & Supervisory Board Members including two Outside Audit & Supervisory Board Members.

The candidates for Audit & Supervisory Board Members are as follows:

Candidate No.	Name		Position in the Company and significant concurrent positions outside the Company, etc.
1	Kenji Tamamaki	Reelection	Standing Audit & Supervisory Board Member
2	Hajime Murakami	Reelection Outside Independent	Partner, Chuo Sogo Law Office, P.C., Outside Audit & Supervisory Board Member, SOGA & Co.,Ltd., Outside Audit & Supervisory Board Member, Tannan Construction Co., Ltd., Special Professor, Graduate School of Law, Kyoto University
3	Yuki Onishi	Reelection Outside Independent	Outside Director and Audit Committee Member, HIGASHI TWENTY ONE CO.,LTD., External Auditor, Silicon Studio Corporation, Outside Director and Audit Committee Member, CREATE CORPORATION

Candidate No.	Name (Date of birth)	Career summary, position in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned	
1	Kenji Tamamaki (August 19, 1961) Reelection	Apr. 1984	Joined Sogo Co., Ltd.	9,700
		Sep. 2001	Joined the Company	
		Apr. 2004	General Manager of the Administration Division	
		Apr. 2006	General Manager of the Finance & Accounting Department	
		Apr. 2009	General Manager in charge of Production Management of the Product Business Division	
		Oct. 2015	General Manager of the Administration Department	
		June 2021	Standing Audit & Supervisory Board Member (current position)	
	Number of years in office as an Audit & Supervisory Board Member (at the conclusion of this meeting)		3 years	
	Attendance at Board of Directors meetings for the fiscal year 2023		13/13 meetings	
	Reasons for nomination as candidate for Audit & Supervisory Board Member Kenji Tamamaki has had a wealth of experience mainly in the administrative division since joining the Company in 2001. He has also served as General Manager in charge of Production Management since 2009 and has knowledge of internal operations. Furthermore, he is appropriately executing his duties as Standing Audit & Supervisory Board Member. Therefore, the Company believes that he is qualified to serve as an Audit & Supervisory Board Member of the Company.			
	Special interests There is no special interest between the candidate and the Company.			
2	Hajime Murakami (April 2, 1970) Reelection Outside Independent	Apr. 1998	Registered as an attorney-at-law, joined Chuo Sogo Law Office, P.C.	0
		Oct. 2004	Partner, Chuo Sogo Law Office, P.C. (current position)	
		June 2019	Outside Audit & Supervisory Board Member, SOGA & Co.,Ltd. (current position)	
		June 2020	Outside Audit & Supervisory Board Member of the Company (current position)	
		May 2021	Outside Audit & Supervisory Board Member, Tannan Construction Co., Ltd. (current position)	
		Apr. 2022	Special Professor, Graduate School of Law, Kyoto University (current position)	
	Number of years in office as an Audit & Supervisory Board Member (at the conclusion of this meeting)		4 years	
	Attendance at Board of Directors meetings for the fiscal year 2023		13/13 meetings	
	Reasons for nomination as candidate for Audit & Supervisory Board Member The Company expects that Hajime Murakami will utilize his experience as an Outside Audit & Supervisory Board Member, in addition to his professional knowledge and experience as an attorney-at-law, in the Company's auditing system. There is no business relationship between the Company and the entity for which Mr. Murakami concurrently serves as an officer.			
	Special interests There is no special interest between the candidate and the Company.			

Candidate No.	Name (Date of birth)	Career summary, position in the Company, and significant concurrent positions outside the Company	Number of the Company's shares owned	
3	Yuki Onishi (April 12, 1963) Reelection Outside Independent	Apr. 1984	Joined NEW COSMOS ELECTRIC CO., LTD.	0
		Mar. 1992	Established CAT Ltd. as Representative Director and President	
		Apr. 1997	Established CAT Co., Ltd. as Representative Director and President	
		Mar. 2014	Merged with KCS Data Corporation, established KCS Solutions Corporation as Representative Director and President	
		June 2018	Advisor, KCS Solutions Corporation	
		Apr. 2019	Chief Management Consultant (non-standing), Tenjinbashi Accounting Office	
		June 2019	Outside Director and Audit Committee Member, HIGASHI TWENTY ONE CO.,LTD. (current position)	
		June 2020	Outside Audit & Supervisory Board Member of the Company (current position)	
		Feb. 2022	External Auditor, Silicon Studio Corporation (current position)	
		June 2022	Outside Director and Audit Committee Member, CREATE CORPORATION (current position)	
		Number of years in office as an Audit & Supervisory Board Member (at the conclusion of this meeting)	4 years	
		Attendance at Board of Directors meetings for the fiscal year 2023	13/13 meetings	
		Reasons for nomination as candidate for Audit & Supervisory Board Member The Company expects that Yuki Onishi will utilize her wealth of experience and deep insight in empowering women and other areas, owing to her more than 20 years of practical experience as a female entrepreneurial executive, in the Company's auditing system. There is no business relationship between the Company and the entity for which Ms. Onishi concurrently serves as an officer.		
		Special interest There is no special interest between the candidate and the Company.		

- Notes:
1. Hajime Murakami is a candidate for outside Audit & Supervisory Board Member. Furthermore, he has been designated as an independent officer as provided for by Tokyo Stock Exchange, Inc. and has been notified to the Exchange. If he is elected as proposed, he will continue to be an independent officer.
 2. Yuki Onishi is a candidate for outside Audit & Supervisory Board Member. Furthermore, she has been designated as an independent officer as provided for by Tokyo Stock Exchange, Inc. and has been notified to the Exchange. If she is elected as proposed, she will continue to be an independent officer.
 3. The Company has entered into a liability insurance contract for officers, etc. with an insurance company as provided for in Article 430-3, paragraph (1) of the Companies Act, and the insurance contract covers damages such as the costs of disputes and compensation for damages incurred by the insured due to company lawsuits, third-party lawsuits, shareholder derivative lawsuits, etc. The candidates will be included in the insured under the insurance contract. Furthermore, the Company plans to renew the insurance contract with the same terms at the next renewal.

(Reference) Skill matrix of candidates for Audit & Supervisory Board Member

Knowledge and experience, etc. possessed by the candidates for Audit & Supervisory Board Member discussed in Proposal No. 2 are as follows:

Knowledge, experience, capability, expertise, and strategic skills	Kenji Tamamaki Standing Audit & Supervisory Board Member	Hajime Murakami Outside Audit & Supervisory Board Member	Yuki Onishi Outside Audit & Supervisory Board Member
Corporate management	●	●	●
Technology and research & development			
Corporate finance	●		●
Legal affairs and risk management	●	●	
Global			
Industrial knowledge			
Clinical experience			
Sustainability	●	●	●
Challenge			
For Patients			